lerdelimumab lerdelimumab lerdelimumab (cat-152, intended trade name trabio) is a human monoclonal antibody and an immunosuppressive drug targeting tgf beta 2. lerdelimumabmonoclonal antibodytypewhole antibodysourcehumantargettgf beta 2clinical dataatc codenonelegal statuslegal status development discontinued identifierscas number285985-06-0 nchemspidernoneuniigx1feu3qsm ny (what is this?) (verify) it was being developed to reduce scarring after glaucoma drainage surgery. development was stopped in late 2005 after unsuccessful trial results for that condition.